Q-omics provides the consensus-scored TMEM64 profile across patient tissues and cancer cell-line models. TMEM64 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM64 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, TMEM64 RNA expression shows 20,099 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, THCA, and ACC as cancer lineages where TMEM64 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM64 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM64 survival associations across molecular data types. TMEM64 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM64 RNA expression–survival associations across cancer types. High TMEM64 expression shows unfavorable associations in UVM, LUAD, LIHC, LGG and KICH, but favorable associations in LUSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM64 RNA expression.
This table summarizes TMEM64 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM64. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM64 shows lower tumor expression in THCA, LUAD, KICH and UCEC and higher tumor expression in HNSC and KIRP. The THCA box plot shows higher TMEM64 RNA expression in normal versus tumor tissue (log2 FC = −1.278, t-test p < 0.001).
This table shows molecular features associated with TMEM64 in patient tissues and cancer cell lines. In patient samples, TMEM64 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM64 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
